These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 32553750)

  • 1. The tumour microenvironment of pituitary neuroendocrine tumours.
    Marques P; Grossman AB; Korbonits M
    Front Neuroendocrinol; 2020 Jul; 58():100852. PubMed ID: 32553750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours.
    Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Awad S; Dorward N; Grieve J; Mendoza N; Muquit S; Grossman AB; Balkwill F; Korbonits M
    Acta Neuropathol Commun; 2019 Nov; 7(1):172. PubMed ID: 31703742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour microenvironment and pituitary tumour behaviour.
    Marques P; Korbonits M
    J Endocrinol Invest; 2023 Jun; 46(6):1047-1063. PubMed ID: 37060402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The expression of neural cell adhesion molecule and the microenvironment of pituitary neuroendocrine tumours.
    Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Grieve J; Dorward N; Mendoza N; Nair R; Muquit S; Grossman AB; Korbonits M
    J Neuroendocrinol; 2021 Dec; 33(12):e13052. PubMed ID: 34708902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pituitary tumour fibroblast-derived cytokines influence tumour aggressiveness.
    Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Awad S; Dorward N; Grieve J; Mendoza N; Muquit S; Grossman AB; Balkwill F; Korbonits M
    Endocr Relat Cancer; 2019 Dec; 26(12):853-865. PubMed ID: 31645017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxidative stress in pituitary neuroendocrine tumors: Affecting the tumor microenvironment and becoming a new target for pituitary neuroendocrine tumor therapy.
    Zhou Y; Zhang A; Fang C; Yuan L; Shao A; Xu Y; Zhou D
    CNS Neurosci Ther; 2023 Oct; 29(10):2744-2759. PubMed ID: 37341156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Invited Review: Pathology of pituitary neuroendocrine tumours: present status, modern diagnostic approach, controversies and future perspectives from a neuropathological and clinical standpoint.
    Manojlovic-Gacic E; Bollerslev J; Casar-Borota O
    Neuropathol Appl Neurobiol; 2020 Feb; 46(2):89-110. PubMed ID: 31112312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2--clinical implications.
    Cakir M; Dworakowska D; Grossman A
    J Cell Mol Med; 2010 Nov; 14(11):2585-91. PubMed ID: 20629988
    [No Abstract]   [Full Text] [Related]  

  • 9. Primary Pituitary Carcinoids Do Not Exist: A Reappraisal in the Era of Pituitary Neuroendocrine Tumours.
    Armeni E; Alexandraki KI; Roncaroli F; Grossman AB
    Arch Med Res; 2023 Dec; 54(8):102841. PubMed ID: 37394342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal.
    Villa C; Vasiljevic A; Jaffrain-Rea ML; Ansorge O; Asioli S; Barresi V; Chinezu L; Gardiman MP; Lania A; Lapshina AM; Poliani L; Reiniger L; Righi A; Saeger W; Soukup J; Theodoropoulou M; Uccella S; Trouillas J; Roncaroli F
    Virchows Arch; 2019 Dec; 475(6):687-692. PubMed ID: 31578606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of the tumour microenvironment in the angiogenesis of pituitary tumours.
    Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Dorward N; Grieve J; Mendoza N; Nair R; Muquit S; Grossman AB; Korbonits M
    Endocrine; 2020 Dec; 70(3):593-606. PubMed ID: 32946040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is it time to consider the expression of specific-pituitary hormone genes when typifying pituitary tumours?
    García-Martínez A; Sottile J; Fajardo C; Riesgo P; Cámara R; Simal JA; Lamas C; Sandoval H; Aranda I; Picó A
    PLoS One; 2018; 13(7):e0198877. PubMed ID: 29979686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From Pituitary Adenoma to Pituitary Neuroendocrine Tumors: How Molecular Pathways may Impact the Therapeutic Management?
    Chiloiro S; De Marinis L
    Endocr Metab Immune Disord Drug Targets; 2021; 21(10):1744-1759. PubMed ID: 34425741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3D-3-culture: A tool to unveil macrophage plasticity in the tumour microenvironment.
    Rebelo SP; Pinto C; Martins TR; Harrer N; Estrada MF; Loza-Alvarez P; Cabeçadas J; Alves PM; Gualda EJ; Sommergruber W; Brito C
    Biomaterials; 2018 May; 163():185-197. PubMed ID: 29477032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the tumor microenvironment in digestive neuroendocrine tumors.
    Cuny T; de Herder W; Barlier A; Hofland LJ
    Endocr Relat Cancer; 2018 Nov; 25(11):R519-R544. PubMed ID: 30306777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stem Cell Transcription Factor Sox2 Is Expressed in a Subset of Folliculo-stellate Cells of Growth Hormone-Producing Pituitary Neuroendocrine Tumours and Its Expression Shows No Association with Tumour Size or IGF1 Levels: a Clinicopathological Study of 109 Cases.
    Soukup J; Česák T; Hornychová H; Michalová K; Michnová Ľ; Netuka D; Čáp J; Gabalec F
    Endocr Pathol; 2020 Dec; 31(4):337-347. PubMed ID: 32632839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the role of the tumor microenvironment in refractory pituitary tumor pathogenesis.
    Ben-Shlomo A
    Pituitary; 2023 Jun; 26(3):263-265. PubMed ID: 36870010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The biological behavior and clinical outcome of pituitary adenoma are affected by the microenvironment.
    Li Y; Ren X; Gao W; Cai R; Wu J; Liu T; Chen X; Jiang D; Chen C; Cheng Q; Wu A; Cheng W
    CNS Neurosci Ther; 2024 May; 30(5):e14729. PubMed ID: 38738958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modifying the tumour microenvironment and reverting tumour cells: New strategies for treating malignant tumours.
    Cheng YQ; Wang SB; Liu JH; Jin L; Liu Y; Li CY; Su YR; Liu YR; Sang X; Wan Q; Liu C; Yang L; Wang ZC
    Cell Prolif; 2020 Aug; 53(8):e12865. PubMed ID: 32588948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours.
    Iacovazzo D; Chiloiro S; Carlsen E; Bianchi A; Giampietro A; Tartaglione T; Bima C; Bracaccia ME; Lugli F; Lauretti L; Anile C; Gessi M; Colosimo C; Rindi G; Pontecorvi A; Korbonits M; De Marinis L
    Endocrine; 2020 Mar; 67(3):651-658. PubMed ID: 31875303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.